1.Diagnosis and treatment of dyslipidemia.
Korean Journal of Medicine 2008;74(4):358-362
No abstract available.
Dyslipidemias
;
Fibric Acids
;
Niacin
2.Refocusing Peroxisome Proliferator Activated Receptor-alpha: A New Insight for Therapeutic Roles in Diabetes.
Diabetes & Metabolism Journal 2013;37(5):326-332
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, risks of macrovascular and microvascular complications have still remained, and development of new therapeutic strategies is needed. Recent data have shown that peroxisome proliferator activated receptor-alpha (PPAR-alpha) plays a pivotal role in the regulation of lipid homeostasis, fatty acid oxidation, cellular differentiation, and immune response such as inflammation or vascularization related to diabetic complication. This review will re-examine the metabolic role of PPAR-alpha, summarize data from clinical studies on the effect of PPAR-alpha agonist in diabetes, and will discuss the possible therapeutic role of PPAR-alpha activation.
Cardiovascular Diseases
;
Diabetes Complications
;
Fibric Acids
;
Homeostasis
;
Inflammation
;
PPAR alpha*
3.Refocusing Peroxisome Proliferator Activated Receptor-alpha: A New Insight for Therapeutic Roles in Diabetes.
Diabetes & Metabolism Journal 2013;37(5):326-332
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, risks of macrovascular and microvascular complications have still remained, and development of new therapeutic strategies is needed. Recent data have shown that peroxisome proliferator activated receptor-alpha (PPAR-alpha) plays a pivotal role in the regulation of lipid homeostasis, fatty acid oxidation, cellular differentiation, and immune response such as inflammation or vascularization related to diabetic complication. This review will re-examine the metabolic role of PPAR-alpha, summarize data from clinical studies on the effect of PPAR-alpha agonist in diabetes, and will discuss the possible therapeutic role of PPAR-alpha activation.
Cardiovascular Diseases
;
Diabetes Complications
;
Fibric Acids
;
Homeostasis
;
Inflammation
;
PPAR alpha*
4.Combination pharmacotherapy in lipid management.
Journal of the Korean Medical Association 2015;58(8):745-749
Latest guidelines on lipid management recommend statins as the first-line therapy. Because limited evidence is available on cardiovascular outcomes with varying statin-nonstatin combinations, recommendation levels for these regimens have been weak. However, a recent trial has demonstrated the additive effect of the statin-ezetimibe combination. The statin-fibrate combination has shown an effect in certain subgroups and on diabetic microangiopathy. Recent trials using the statin-niacin combination have been largely negative, whereas the statin-omega-3 fatty acids combination demonstrated a positive effect only in one study. Identifying the benefits and limitations of each combination is important for the best possible management of patients.
Diabetic Angiopathies
;
Drug Therapy*
;
Ezetimibe
;
Fatty Acids
;
Fibric Acids
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Niacin
5.An Update on Hypertriglyceridemia-Induced Acute Pancreatitis.
Korean Journal of Medicine 2018;93(6):518-524
Hypertriglyceridemia a major cause of acute pancreatitis, accounting for up to 10% of all cases. The pathophysiological mechanism of hypertriglyceridemia-induced acute pancreatitis (HTGP) is presumed to involve the hydrolysis of triglycerides by pancreatic lipase resulting in an excess of free fatty acids and elevated chylomicrons, which are thought to increase plasma viscosity and induce ischemia and inflammation in pancreatic tissue. Although the clinical course of HTGP is similar to other forms of acute pancreatitis, the clinical severity and associated complications are significantly higher in patients with HTGP. Therefore, an accurate diagnosis is essential for treatment and prevention of disease recurrence. At present, there are no approved guidelines for the management of HTGP. Different treatment modalities such as apheresis/plasmapheresis, insulin, heparin, fibric acids, and omega-3 fatty acids have been successfully implemented to reduce serum triglycerides. Following acute phase management, lifestyle modifications including dietary adjustments and drug therapy are important for the long-term management of HTGP and the prevention of relapse. Additional studies are required to produce generalized and efficient treatment guidelines for HTGP.
Chylomicrons
;
Diagnosis
;
Drug Therapy
;
Fatty Acids, Nonesterified
;
Fatty Acids, Omega-3
;
Fibric Acids
;
Heparin
;
Humans
;
Hydrolysis
;
Hypertriglyceridemia
;
Inflammation
;
Insulin
;
Ischemia
;
Life Style
;
Lipase
;
Pancreatitis*
;
Plasma
;
Recurrence
;
Triglycerides
;
Viscosity
6.Small Dense Low-density Lipoprotein and Cardiovascular Disease.
Journal of Lipid and Atherosclerosis 2012;1(1):1-9
Cardiovascular disease (CVD) is the leading cause of death worldwide and small dense low-density lipoprotein (sdLDL) has been suggested to be a potential risk factor for cardiovascular disease (CVD). We reviewed published studies on formation and measurement of sdLDL, as well as relationship between LDL subfractions and CVD. sdLDL particle formation is highly dependent on triglycerides (TG) levels, and the physicochemical properties of sdLDL particles provide a potential for increased atherogenicity. Various conditions (e.g. hypertriglyceridemia, diabetes mellitus, metabolic syndrome, chronic renal failure and HIV infections) with increased cardiometabolic risk are associated with increased sdLDLs. Most studies suggest that sdLDL particles are associated with increased prevalence of clinical and subclinical CVDs, as well as non-coronary forms of atherosclerosis. Moreover, LDL size seems to be an important determinant of the progression of CVD. Therapeutic modulation (mostly fibrates, but also some statins, as well as niacin and thiazolidinediones) of small LDL size, number and distribution may decrease CVD risk. However, no definitive causal relationship is yet established, probably due to the close association between sdLDL and triglycerides and other risk factors.
Atherosclerosis
;
Cardiovascular Diseases
;
Cause of Death
;
Diabetes Mellitus
;
Fibric Acids
;
HIV
;
Hypertriglyceridemia
;
Kidney Failure, Chronic
;
Lipoproteins
;
Niacin
;
Prevalence
;
Risk Factors
;
Triglycerides
7.Activation of PPARalpha Attenuates IFNgamma and IL-1beta-induced Cell Proliferation in Astrocytes: Involvement of IL-6 Independent Pathway.
Jin Koo LEE ; Eun Min SEO ; Sang Soo LEE ; Soo Hyun PARK ; Yun Beom SIM ; Jun Sub JUNG ; Seon Mi KIM ; Hong Won SUH
The Korean Journal of Physiology and Pharmacology 2010;14(3):185-189
The present study demonstrates the effect of fibrates, agonists of PPARalpha on cytokines-induced proliferation in primary cultured astrocytes. Alone or combination treatment with cytokines, such as IL-1beta (10 ng/ml), IFNgamma (10 ng/ml), and TNF-alpha (10 ng/ml) cause a significant increase of cell proliferation in a time-dependent manner. Treatment of astrocytes with bezafibrate and fenofibrate (0, 5, and 10 micrometer) reduced the IFNgamma and IL-1beta-induced cell proliferation in a dose-dependent manner. To address the involvement of IL-6 on the IFNgamma and IL-1beta-induced cell proliferation, released IL-6 level was measured. IFNgamma and IL-1beta cause an increase of released IL-6 protein level in a time-dependent manner. Furthermore, pretreatment with IL-6 antibody (0, 0.1, 1, 2.5, and 5 ng/ml) dose-dependently inhibited the IFNgamma and IL-1beta-induced cell proliferation. However, bezafibrate and fenofibrate did not affect increased mRNA and protein levels of IL-6 in IFNgamma and IL-1beta-stimulated astrocytes. Taken together, these results clearly suggest that activation of PPARalpha attenuates the IFNgamma and IL-1beta-induced cell proliferation through IL-6 independent pathway.
Astrocytes
;
Bezafibrate
;
Cell Proliferation
;
Cytokines
;
Fenofibrate
;
Fibric Acids
;
Interleukin-6
;
PPAR alpha
;
RNA, Messenger
;
Tumor Necrosis Factor-alpha
8.Hypertriglyceridemia and Cardiovascular Diseases: Revisited.
Seung Hwan HAN ; Stephen J NICHOLLS ; Ichiro SAKUMA ; Dong ZHAO ; Kwang Kon KOH
Korean Circulation Journal 2016;46(2):135-144
Residual cardiovascular risk and failure of high density lipoprotein cholesterol raising treatment have refocused interest on targeting hypertriglyceridemia. Hypertriglyceridemia, triglyceride-rich lipoproteins, and remnant cholesterol have demonstrated to be important risk factors for cardiovascular disease; this has been demonstrated in experimental, genetic, and epidemiological studies. Fibrates can reduce cardiovascular event rates with or without statins. High dose omega-3 fatty acids continue to be evaluated and new specialized targeting treatment modulating triglyceride pathways, such as inhibition of apolipoprotein C-III and angiopoietin-like proteins, are being tested with regard to their effects on lipid profiles and cardiovascular outcomes. In this review, we will discuss the role of hypertriglyceridemia, triglyceride-rich lipoproteins and remnant cholesterol on cardiovascular disease, and the potential implications for treatment stargeting hypertriglyceridemia.
Apolipoprotein C-III
;
Cardiovascular Diseases*
;
Cholesterol
;
Cholesterol, HDL
;
Epidemiologic Studies
;
Fatty Acids, Omega-3
;
Fibric Acids
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Hypertriglyceridemia*
;
Lipoproteins
;
Risk Factors
;
Triglycerides
9.Update on the Pharmacologic Agents for Dyslipidemia.
Journal of Korean Diabetes 2015;16(4):269-275
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Cholesterol Ester Transfer Proteins
;
Dyslipidemias*
;
Fatty Acids, Omega-3
;
Fibric Acids
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Niacin
;
Prescriptions
;
Proprotein Convertases
;
Ezetimibe
10.Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-alpha Agonist for Treating Cardiovascular Disease.
Young Ran KANG ; Choong Hwan KWAK ; Jin Yong HWANG
Korean Circulation Journal 2007;37(12):599-608
Peroxisome proliferator-activated receptor (PPAR)-alpha belongs to the nuclear family of ligand-activated transcriptional factors. The main role of PPAR-alpha is to activate the expression of the genes that are involved in fatty acid oxidation to achieve energy homeostasis. Fibrates are a known class of PPAR-alpha agonists, and they been used clinically for their effects of lowering triglycerides and elevating high-density lipoprotein-cholesterol (HDL-C). Further, recent experimental studies have demonstrated the anti-inflammatory and anti-atherosclerotic actions of PPAR-alpha agonists directly on the vascular wall. PPAR agonists are currently emerging as a promising therapeutic option to control systemic and vascular atherogenic factors. Regardless of their strong anti-atherosclerotic properties, large clinical studies have demonstrated inconsistent results for the cardioprotective effect of PPAR-alpha agonists; moreover, it has been observed that they did not decrease the total mortality, which stands in contrast to the statin trials. This review summarizes the current knowledge regarding the PPAR biology and the mechanisms of the effects of PPAR-alpha on lipid metabolism, the vessel wall and the cardiac metabolism. We also describe the results and lessons learned from the important clinical trials of PPAR-alpha agonists and we discuss these drugs' efficacy and safety.
Biology
;
Cardiovascular Diseases*
;
Fibric Acids
;
Homeostasis
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Lipid Metabolism
;
Metabolism
;
Mortality
;
Nuclear Family
;
Peroxisome Proliferator-Activated Receptors
;
Peroxisomes*
;
Triglycerides